Pliant Therapeutics, Inc. terminated its "Controlled Equity Offering Sales Agreement" from July 2, 2021, with Cantor Fitzgerald & Co., effective March 27, 2026. No shares were sold under the 2021 Sales Agreement prior to its termination. The Company is not subject to any termination penalties related to the 2021 Sales Agreement. Pliant Therapeutics previously entered into a new "Sales Agreement" with Leerink Partners LLC on March 30, 2026, for an at-the-market (ATM) offering program. Under the new ATM program, the Company may offer and sell shares of its common stock with an aggregate offering price of up to $50.0 million.